Transformed Indolent B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

  A Phase 1 clinical trial is evaluating a triple-drug regimen consisting of mosunetuzumab, polatuzumab vedotin, and lenalidomide for relapsed…

• CLINICAL_TRIALS trial_result · 2025-01-07
  Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]

  Phase 2 trial of ibrutinib in patients with relapsed or refractory transformed indolent B-cell non-Hodgkin lymphoma; results have been poste…